Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0692-8
Abstract: SummaryBackground Pazopanib is approved for metastatic renal cell carcinoma (RCC). We assessed the safety and efficacy of pazopanib with a low fat meal (LFM): read more here.
Keywords: renal cell; low fat; cell carcinoma; meal ... See more keywords
Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma (RCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.683
Abstract: 683Background: Pazopanib, a highly lipophilic standard first-line therapy for metastatic RCC, is conventionally taken in a fasting state but has significant gastrointestinal toxicities and 96% of ingested drug is fecally excreted, with major financial implications.… read more here.
Keywords: low fat; fat meal; pazopanib low; meal palm ... See more keywords